Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...
Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or ...
Black Diamond Therapeutics (NASDAQ:BDTX) reported encouraging Phase 2 data for its drug candidate BDTX-1535 in the treatment ...
Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.
Trying to defeat the Ebony Warrior in Skyrim? Here's why he's so tough, and the strategy for sending him to Sovngarde.